Daratumumab is widely used in multiple myeloma (MM) and light chain amyloidosis (AL amyloidosis). The purpose of this study was to identify adverse event (AE) signals for daratumumab through the FDA A
Data from Physical Exam Form: Cardiovascular System [CRF 6] Study Description A prospective proof of concept study of subjects who had successfully suppressed their HIV-1 RNA levels for a minimum of 6